Special Issue "Mitochondrial Drugs for Neurodegenerative Diseases"

Quicklinks

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: closed (31 August 2012)

Special Issue Editor

Guest Editor
Dr. P. Hemachandra Reddy
Neurogenetics Laboratory, Neuroscience Division, Oregon National Primate Research Center, West Campus, Oregon Health and Science University, 505 N.W., 185th Avenue Beaverton, OR 97006, USA
E-Mail: reddyh@ohsu.edu
Phone: +1 503 418 2625 (office); +1 503 418 2627 (lab)
Fax: +1 503 418 2501
Interests: aging; neurodegenerative diseases; gene expression analysis; transgenic mouse models; mitochondrial biology; mitochondrial function/dysfunction; mitochondrial therapeutics; mitochondrial dynamics

Special Issue Information

Dear Colleagues,

Mitochondria, cytoplasmic organelles found in virtually every eukaryotic cell, are essential for life and death. In the last two decades tremendous progress has been made in mitochondrial research and has provided significant findings to link mitochondrial dysfunction in neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, Amyotrophic Lateral Sclerosis and Huntington’s disease. Further, recently, several groups developed mitochondrial-targeted antioxidants and tested in cell and mouse models of neurodegenerative diseases. The purpose of this special issue is to assess the current status of mitochondrial therapeutics, particularly mitochondrially targeted molecules in aging and age-related neurodegenerative diseases, and also to discuss the issues related to the development of molecules that cross blood brain barrier, reach mitochondria and protect mitochondria from the toxicity of mutant proteins and other toxic insults.

Prof. Dr. P. Hemachandra Reddy
Guest Editor

Keywords

  • Mitochondria
  • Aging
  • Neurodegenerative Disease
  • Mitochondrial-targeted antioxidants
  • Cyclophilin D
  • Mitochondrial permeability pore
  • Alzheimer\'s Disease
  • Parkinson\'s Disease
  • Calcium Dyshomeostasis

Published Papers (10 papers)

by , ,  and
Pharmaceuticals 2013, 6(1), 108-123; doi:10.3390/ph6010108
Received: 5 November 2012; in revised form: 13 December 2012 / Accepted: 14 January 2013 / Published: 18 January 2013
Show/Hide Abstract | PDF Full-text (241 KB) | HTML Full-text | XML Full-text

by ,  and
Pharmaceuticals 2012, 5(10), 1103-1119; doi:10.3390/ph5101103
Received: 5 September 2012; in revised form: 4 October 2012 / Accepted: 8 October 2012 / Published: 16 October 2012
Show/Hide Abstract | Cited by 3 | PDF Full-text (460 KB) | HTML Full-text | XML Full-text

by  and
Pharmaceuticals 2010, 3(6), 1936-1948; doi:10.3390/ph3061936
Received: 10 May 2010; in revised form: 10 June 2010 / Accepted: 14 June 2010 / Published: 14 June 2010
Show/Hide Abstract | Cited by 1 | PDF Full-text (250 KB) | HTML Full-text | XML Full-text

by
Pharmaceuticals 2010, 3(4), 839-915; doi:10.3390/ph3040839
Received: 31 December 2009; in revised form: 22 March 2010 / Accepted: 23 March 2010 / Published: 25 March 2010
Show/Hide Abstract | Cited by 27 | PDF Full-text (810 KB) | HTML Full-text | XML Full-text

by , ,  and
Pharmaceuticals 2010, 3(2), 345-368; doi:10.3390/ph3020345
Received: 23 December 2009; in revised form: 20 January 2010 / Accepted: 25 January 2010 / Published: 28 January 2010
Show/Hide Abstract | Cited by 9 | PDF Full-text (413 KB) | HTML Full-text | XML Full-text

by , , , , , , ,  and
Pharmaceuticals 2010, 3(1), 158-187; doi:10.3390/ph3010158
Received: 28 November 2009; in revised form: 11 January 2010 / Accepted: 14 January 2010 / Published: 19 January 2010
Show/Hide Abstract | Cited by 5 | PDF Full-text (815 KB) | HTML Full-text | XML Full-text

by , , , , , , , ,  and
Pharmaceuticals 2009, 2(3), 250-286; doi:10.3390/ph2030250
Received: 5 November 2009; in revised form: 21 December 2009 / Accepted: 22 December 2009 / Published: 23 December 2009
Show/Hide Abstract | PDF Full-text (437 KB) | HTML Full-text | XML Full-text
abstract graphic

by , , , ,  and
Pharmaceuticals 2009, 2(3), 287-298; doi:10.3390/ph2030287
Received: 23 October 2009; in revised form: 14 December 2009 / Accepted: 16 December 2009 / Published: 23 December 2009
Show/Hide Abstract | Cited by 4 | PDF Full-text (919 KB) | HTML Full-text | XML Full-text
abstract graphic

by
Pharmaceuticals 2009, 2(3), 150-167; doi:10.3390/ph2030150
Received: 19 November 2009; in revised form: 27 November 2009 / Accepted: 2 December 2009 / Published: 3 December 2009
Show/Hide Abstract | Cited by 8 | PDF Full-text (328 KB) | HTML Full-text | XML Full-text

by , , ,  and
Pharmaceuticals 2009, 2(3), 134-149; doi:10.3390/ph203134
Received: 29 September 2009; in revised form: 26 November 2009 / Accepted: 30 November 2009 / Published: 1 December 2009
Show/Hide Abstract | Cited by 6 | PDF Full-text (213 KB) | HTML Full-text | XML Full-text
abstract graphic

Last update: 4 March 2014

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert